RxDoctor Payments Data

Nicole Schneider, NP

Nurse Practitioner · Eau Claire, WINPI 1801082979

Payments from drug & device makers

$1,648in general payments, 2019–2025

Across 42 payments — averaging $39.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$817
  • Sanofi-aventis U.S. LLC$372
  • Sequel Med Tech, LLC$118
  • Boehringer Ingelheim$117
  • Medtronic$89
  • Novo Nordisk$63
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$1,61698%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,648 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$24,151
Medicare patients
142
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide175$183,274
MounjaroTirzepatide144$168,470
OzempicSemaglutide103$133,393
JardianceEmpagliflozin97$96,294
FarxigaDapagliflozin Propanediol28$30,977
Tresiba Flextouch U-200Insulin Degludec22$29,191
Humalog Kwikpen U-100Insulin Lispro67$27,457
Humulin R U-500 KwikpenInsulin Regular, Human14$22,359
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog52$20,539
Fiasp FlextouchInsulin Aspart (Niacinamide)13$19,718
Novolog FlexpenInsulin Aspart49$17,655
Lantus SolostarInsulin Glargine,hum.Rec.Anlog107$16,067
Tresiba Flextouch U-100Insulin Degludec27$15,986
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$13,040
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$11,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro$18$352,654330 claims
Novo NordiskOzempic, Novolog$63$139,198120 claims
Boehringer IngelheimJardiance$117$96,29497 claims
AstraZenecaFarxiga$12$30,97728 claims
Sanofi-aventis U.S. LLCLantus$372$75912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →